Inflammatory bowel disease prognostics

摘要

NZ 595471 Disclosed is a method for aiding in the prognosis of Crohn’s disease (CD) in an individual diagnosed with CD, said method comprising: (a) analyzing a sample obtained from said individual to determine the presence, level or genotype of a combination of serological markers and genetic markers, wherein said serological markers comprise anti-Saccharomyces cerevisiae immunoglobulin A (ASCA-IgA), anti-Saccharomyces cerevisiae immunoglobulin G (ASCAIgG), an anti-outer membrane protein C (anti-OmpC) antibody, an anti-CBir-1 antibody, an anti-I2 antibody, and a perinuclear anti-neutrophil cytoplasmic antibody (pANCA), and wherein said genetic markers comprise SNP8 (R702W), SNP12 (G908R), and SNP13 (3020InsC) in the NOD2 gene; (b) applying a quartile analysis to said serological markers to obtain a quartile sum score (QSS) for said individual by converting the presence or level of said serological markers into a quartile score and summing said quartile score for each of said serological markers; and (c) aiding in the prognosis of CD by determining a risk for said individual of developing a CD complication over time, wherein said risk is determined by comparing said QSS and the genotype of said genetic markers for said individual to a sero-genetic model that provides a cumulative probability of developing a CD complication over time.